Immunotherapy for cardiovascular disease.
Anti-Inflammatory Agents
/ therapeutic use
Antibodies, Monoclonal, Humanized
/ adverse effects
Atherosclerosis
/ complications
Cardiovascular Diseases
/ mortality
Coronary Artery Disease
/ prevention & control
Cytokines
/ drug effects
Humans
Immunologic Factors
/ therapeutic use
Immunotherapy
/ methods
Inflammation
/ drug therapy
Interleukin-1beta
/ antagonists & inhibitors
Netherlands
/ epidemiology
Randomized Controlled Trials as Topic
Cardiovascular disease
Coronary artery disease
Cytokines
Inflammation
Novel targets
Novel therapies
Journal
European heart journal
ISSN: 1522-9645
Titre abrégé: Eur Heart J
Pays: England
ID NLM: 8006263
Informations de publication
Date de publication:
21 12 2019
21 12 2019
Historique:
received:
07
12
2018
revised:
11
02
2019
accepted:
17
04
2019
pubmed:
24
5
2019
medline:
27
10
2020
entrez:
24
5
2019
Statut:
ppublish
Résumé
The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequivocally proven that inflammation is a key driver of atherosclerosis and that targeting inflammation, in this case by using an anti-interleukin-1β antibody, improves cardiovascular disease (CVD) outcomes. This is especially true for CVD patients with a pro-inflammatory constitution. Although CANTOS has epitomized the importance of targeting inflammation in atherosclerosis, treatment with canakinumab did not improve CVD mortality, and caused an increase in infections. Therefore, the identification of novel drug targets and development of novel therapeutics that block atherosclerosis-specific inflammatory pathways and exhibit limited immune-suppressive side effects, as pursued in our collaborative research centre, are required to optimize immunotherapy for CVD. In this review, we will highlight the potential of novel immunotherapeutic targets that are currently considered to become a future treatment for CVD.
Identifiants
pubmed: 31121017
pii: 5497815
doi: 10.1093/eurheartj/ehz283
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antibodies, Monoclonal, Humanized
0
Cytokines
0
IL1B protein, human
0
Immunologic Factors
0
Interleukin-1beta
0
canakinumab
37CQ2C7X93
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3937-3946Informations de copyright
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.